Top

Published in:

01-02-2003

Transcriptional regulation of osteopontin and the metastatic phenotype: Evidence for a Ras-activated enhancer in the human OPN promoter

Authors: David T. Denhardt, Devra Mistretta, Ann F. Chambers, Shuba Krishna, Joseph F. Porter, Srilatha Raghuram, Susan R. Rittling

Published in: Clinical & Experimental Metastasis | Issue 1/2003

Title: Transcriptional regulation of osteopontin and the metastatic phenotype: Evidence for a Ras-activated enhancer in the human OPN promoter
Authors: David T. Denhardt
Devra Mistretta
Ann F. Chambers
Shuba Krishna
Joseph F. Porter
Srilatha Raghuram
Susan R. Rittling
Publication date: 01-02-2003
Publisher: Kluwer Academic Publishers
Published in: Clinical & Experimental Metastasis / Issue 1/2003
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1023/A:1022550721404

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 1/2003

Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: Role in epithelial cancer cell invasion, proliferation and nuclear regulation

Breast cancer metastasis suppressor 1: Update

Osteopontin and colon cancer progression

Introduction

Regulation of cancer metastasis by stress pathways

Collapsin response mediator protein-1: A novel invasion-suppressor gene

Keynote webinar | Spotlight on antibody–drug conjugates in cancer